Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1

Frontiers in Immunology
Yu-Tzu TaiKenneth C Anderson

Abstract

Immunomodulatory drugs and monoclonal antibody-based immunotherapies have significantly improved the prognosis of the patients with multiple myeloma (MM) in the recent years. These new classes of reagents target malignant plasma cells (PCs) and further modulate the immune microenvironment, which prolongs anti-MM responses and may prevent tumor occurrence. Since MM remains an incurable cancer for most patients, there continues to be a need to identify new tumor target molecules and investigate alternative cellular approaches using gene therapeutic strategies and novel treatment mechanisms. Osteoclasts (OCs), as critical multi-nucleated large cells responsible for bone destruction in >80% MM patients, have become an attractive cellular target for the development of novel MM immunotherapies. In MM, OCs are induced and activated by malignant PCs in a reciprocal manner, leading to osteolytic bone disease commonly associated with this malignancy. Significantly, bidirectional interactions between OCs and MM cells create a positive feedback loop to promote MM cell progression, increase angiogenesis, and inhibit immune surveillance via both cell-cell contact and abnormal production of multiple cytokines/chemokines. Most recently, hyper-...Continue Reading

References

Dec 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R BatailleC Alexandre
Oct 1, 1995·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·D E HughesB F Boyce
Nov 5, 1999·Biochemical and Biophysical Research Communications·N J HorwoodM T Gillespie
Nov 24, 1999·The Journal of Clinical Investigation·L I PlotkinT Bellido
Feb 15, 2000·The Journal of Biological Chemistry·Y AzumaA Kudo
Sep 1, 2000·Science·S L Teitelbaum
Jan 6, 2001·Acta Oncologica·M A DimopoulosR Alexanian
Sep 20, 2001·Proceedings of the National Academy of Sciences of the United States of America·R N PearseY Choi
Nov 5, 2002·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·G David Roodman
Dec 3, 2002·Nature Reviews. Cancer·Teru Hideshima, Kenneth C Anderson
Jul 9, 2003·The Journal of Experimental Medicine·Mohammed Javeed I AnsariMohamed H Sayegh
Dec 26, 2003·The New England Journal of Medicine·Erming TianJohn D Shaughnessy
Jan 30, 2004·Cytokine & Growth Factor Reviews·Steeve Kwan TatYannick Fortun
Apr 16, 2004·The New England Journal of Medicine·G David Roodman
Dec 21, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S Vincent RajkumarUNKNOWN Eastern Cooperative Oncology Group
Aug 19, 2006·Blood·Nicola GiulianiG David Roodman
Nov 8, 2006·The Journal of Experimental Medicine·Kojiro SatoHiroshi Takayanagi
Jan 16, 2007·Nature·Marc A GavinAlexander Y Rudensky
Feb 10, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yoichi TanakaToshio Matsumoto
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Junzo HamanishiShingo Fujii
Mar 24, 2007·Nature Reviews. Immunology·Hiroshi Takayanagi
Apr 28, 2007·Biochemical and Biophysical Research Communications·Yong Gil KimHee-Bom Moon
Jun 22, 2007·Leukemia·I von MetzlerO Sezer

❮ Previous
Next ❯

Citations

Oct 26, 2018·Pharmaceutics·Sonia ValletKlaus Podar
Jul 6, 2019·Frontiers in Immunology·Maria-Bernadette MadelClaudine Blin-Wakkach
Jul 7, 2019·Expert Opinion on Biological Therapy·Yu-Tzu Tai, Kenneth C Anderson
Feb 18, 2020·Journal of Clinical Laboratory Analysis·Xiu-Ping CaiKe-Wei Zhao
Jan 30, 2019·The Cancer Journal·Jacalyn Rosenblatt, David Avigan
Aug 10, 2019·Frontiers in Immunology·Elisabeth Seebach, Katharina F Kubatzky
Mar 11, 2020·Seminars in Cancer Biology·Vijay P KaleManoj K Pandey
Jun 22, 2021·Bone Reports·Konstantin ByrgazovMårten Fryknäs
Dec 14, 2021·Frontiers in Cell and Developmental Biology·Liuhua ZhouLiansheng Wang

❮ Previous
Next ❯

Methods Mentioned

BETA
X-ray

Clinical Trials Mentioned

NCT02431208
NCT02616640
NCT02685826
NCT02807454
NCT02514382
NCT03015922
NCT01997840
NCT02834364
NCT01962792
NCT02548962

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.